The β amyloid deposition, pathologic tau, and neurodegeneration (A-T-N) framework proposed by Jack et al. (2018) is intended to define the diagnosis of AD by the presence of amyloid-β and phosphorylated tau that measured either in plasma, cerebrospinal fluid (CSF), or neuroimaging. This evidence concerns the gene MAPT and Alzheimer disease.